New Delhi: Alembic Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic version of oseltamivir phosphate for oral suspension indicated for treatment of influenza.
The final approval by the US Food & Drug Administration (USFDA) is for the Abbreviated New Drug Application (ANDA) oseltamivir phosphate for oral suspension of strength 6 mg/ml, Alembic Pharmaceuticals said in a regulatory filing.